Jae-Joon Hwang

Jae-Joon Hwang

Auto-generated profile, based on publicly available information

Jae-Joon Hwang

Kyung Hee Univ Hosp Gangdong, Dept Pulm & Crit Care Med, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JHJae-Joon Hwang
Jae-Joon Hwang
SSSeo-Hee Shin
Seo-Hee Shin
YKYe-Jee Kim
Ye-Jee Kim
YOYeon-mok Oh
Yeon-mok Oh
SLSang-Do Lee
Sang-Do Lee
JLJae Seung Lee
Jae Seung Lee
Hwang JJ, et al. J Korean Med Sci. 2020 Jan;35(5):e35. https://doi.org/10.3346/jkms.2020.35.e35

5 April 2017 in Mycoses
Verified
Journal Article
Closed access
PDF file
HCHyoung Il Choi
Hyoung Il Choi
JAJin An
Jin An
JHJae Joon Hwang
Jae Joon Hwang
SMSoo-youn Moon
Soo-youn Moon
JSJun Seong Son
Jun Seong Son

1 June 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
IKIl-Gyu Ko
Il-Gyu Ko
JHJae Joon Hwang
Jae Joon Hwang
BCBok Soon Chang
Bok Soon Chang
SKSang-Hoon Kim
Sang-Hoon Kim
JJJun-Jang Jin
Jun-Jang Jin
CCCheon Woong Choi
Cheon Woong Choi

Verified
Journal Article
Open access
PDF file
JAJin An
Jin An
SPSo Hee Park
So Hee Park
IKIL-GYU KO
IL-GYU KO
JJJun-Jang Jin
Jun-Jang Jin
LHLakkyong Hwang
Lakkyong Hwang
CCCheon Woong Choi
Cheon Woong Choi
Lung injury is characterized by diffuse lung inflammation, alveolar-capillary destruction, and alveolar flooding, resulting in respiratory failure. Polydexyribonucleotide (PDRN) has an anti-inflammatory effect, decreasing inflammatory cytokines, and suppressing apoptosis. Thus, we investigated its efficacy in the treatment of lung injury, which was induced in rats using lipopolysaccharide (LPS). Rats were randomly divided into three groups according to sacrifice time, and each group split into control, lung injury-induced, and lung injury-induced + PDRN-treated groups. Rats were sacrificed 24 h and 72 h after PDRN administration, according to each group. Lung injury was induced by intratracheal instillation of LPS (5 mg/kg) in 0.2 mL saline. Rats in PDRN-treated groups received a single intraperitoneal injection of 0.3 mL distilled water including PDRN (8 mg/kg), 1 h after lung injury induction. Percentages of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive, cleaved caspase-3-, -8-, and -9-positive cells, the ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 (Bcl-2), and expressions of inflammatory cytokines (tumor necrosis factor-α, interleukin-6) were decreased by PDRN treatment in the LPS-induced lung injury rats. Therefore, treatment with PDRN reduced lung injury score. This anti-apoptotic effect of PDRN can be ascribed to the enhancing effect of PDRN on adenosine A2A receptor expression. Based on these results, PDRN might be considered as a new therapeutic agent for the treatment of lung injury.

11 December 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JLJi-Hoon Lee
Ji-Hoon Lee
MPMinA Park
MinA Park
SHSeoungWoo Han
SeoungWoo Han
JHJae Joon Hwang
Jae Joon Hwang
SPSo Young Park
So Young Park
Platelets play an important role in hemostasis, inflammation, and immunity. Mean platelet volume (MPV), considered a marker of platelet function and activation, is associated with increased morbidity and mortality in sepsis, coronary artery disease, and chronic inflammatory disease. However, the clinical characteristics and prognostic significance of MPV changes for patients with pneumonia in the intensive care unit (ICU) have not been investigated. This retrospective study was conducted using data from an operational database of patients admitted to a medical ICU between October 2010 and October 2017. Of 235 adult patients with pneumonia admitted to the ICU, clinical characteristics and in-hospital mortality values were compared according to MPV, ΔMPVday1–2, ΔMPVday1–3, ΔMPVday1–4, and ΔMPVday1–Discharge between those who survived and those who did not. The MPV increased during the first four days for both non-survivors and survivors (P < 0.001). However, repeated measures analysis of variance revealed a significantly higher MPV rate over the first four days in non-survivors than in survivors. Additionally, the ΔMPVday1–2, ΔMPVday1–3, ΔMPVday1–4, and ΔMPVday1–Discharge values were significantly greater in non-survivors than in survivors. For in-hospital mortality, the optimal ΔMPV values were >0.9 fL, P = 0.020; >0.9 fL, P < 0.001; >0.8 fL, P < 0.001; and >1.3 fL, P < 0.001 on day 2, day 3, day 4, and at discharge, respectively. In conclusion, our findings demonstrate that ΔMPV during ICU admission may be used as a prognostic marker of mortality in ICU patients with pneumonia. Repeated MPV measurements throughout hospitalization may improve risk stratification for these patients, which could aid in improving patient outcomes.

28 September 2020 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
PDF file
LHLakkyong Hwang
Lakkyong Hwang
IKIL-GYU KO
IL-GYU KO
JJJun‐Jang Jin
Jun‐Jang Jin
SKSang Hoon Kim
Sang Hoon Kim
CKChang-Ju Kim
Chang-Ju Kim
BOKSOON CHANGBOKSOON CHANG
BOKSOON CHANG